Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥ 20 years at the time of informed consent~* Japanese patients with type 2 diabetes~* Patients who have HbA1c ≥ 7.0% and \< 10.0%~Exclusion Criteria:~* Patients with type 1 diabetes mellitus or with a history of diabetic coma, precoma, or ketoacidosis~* Patients receiving or requiring treatment with insulin~* Patients with a body mass index (BMI) of \< 18.5 kg/m2 or ≥ 35.0 kg/m2~* Patients with clinically evident renal impairment (estimated glomerular filtration rate \[eGFR\] of \< 45 mL/min per 1.73 m2) or clinically significant renal disease~* Patients with fasting plasma glucose ≥ 240 mg/dL

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DS-8500a 25 mg QD (Type: EXPERIMENTAL): DS-8500a 25 mg tablet once daily (QD), orally, for up to 12 weeks, and matching sitagliptin placebo capsule
- DS-8500a 50 mg QD (Type: EXPERIMENTAL): DS-8500a 50 mg QD tablet, orally, once daily for up to 12 weeks, and matching sitagliptin placebo capsule
- DS-8500a 75 mg QD (Type: EXPERIMENTAL): DS-8500a 75 mg QD tablet, orally, once daily for up to 12 weeks, and matching sitagliptin placebo capsule
- placebo (Type: PLACEBO_COMPARATOR): placebo tablet and placebo capsule, orally, once daily for up to 12 weeks to match DS-8500a and sitagliptin, respectively.
- Sitagliptin (Type: ACTIVE_COMPARATOR): capsule, orally, once daily for up to 12 weeks and matching DS-8500 placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).